Podcasts about independent chairman

Synopsis: Bernard Coulie is the President and CEO of Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Bernard discusses the arc of his career and shares his perspective on the European biotech ecosystem compared to the United States, and how that's changed over the last 10 years. He talks about the importance of having access to lots of capital in the early days of starting a company. He discusses fibrotic disease, the high medical need to treat it, and the indications they are pursuing. Finally, he discusses the challenges of focusing on multiple therapeutic areas and the advice he would give to others. Biography: Pliant CEO Bernard Coulie, M.D., Ph.D., brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the company's unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, Dr. Coulie held various positions with increasing responsibilities in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. At Johnson & Johnson, he served as Therapeutic Area Leader Internal Medicine, managing a portfolio of products in GI, metabolic diseases and inflammation/immunology, ranging from early drug discovery through Phase 2 studies. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic (Rochester, MN), Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie serves as Chairman of the Board of Directors of SQZ Biotechnologies, a publicly-traded cell therapy biotechnology company, as Independent Chairman of Dualyx, a privately-held biotechnology company based in Belgium and as an Independent Director at Calypso Biotech, a privately-held biotechnology company based in the Netherlands. Dr. Coulie holds an M.D. and Ph.D. from the University of Leuven, Belgium. He is a board-certified internist and holds an MBA from the Vlerick Management School, Leuven, Belgium.

We catch up with Karen Bach to chat about entrepreneurship, innovation, tech, female founders and much more. Karen is non-exec chair and director with strong scale-up and transaction expertise. She describes herself as a lover of clever tech and is a huge fan of digitalisation and simplification. She chooses to work with teams with energy, passion and transparency. Karen has 30 years of experience in growing international tech and telecoms. She will also be speaking at the next Bradford Alumni Speaker Series event titled "Why I Love Tech" by Karen Bach, Chairman of Amino Technologies Plc, on Wednesday 21 April, 18:00-19:00. Full details and a registration link can be found here. BASS events feature inspiring and stimulating talks from some of our inspirational alumni. They are delivered as online webinars, giving you direct access to the thoughts, ideas, and experiences of our alumni experts and speakers and an opportunity to expand your knowledge and discuss a variety of topics in real-time. https://www.eventbrite.co.uk/e/why-i-love-tech-tickets-146839142829 Today, Karen is Chairman of: Amino Technologies Plc (media tech) Consult Red Ltd (media, IoT & connected device consulting) DeepMatter Plc (chemistry digitisation) and non-exec director of: Datapharm Ltd (health-pharma tech) Escape Hunt Plc (physical and digital escape rooms). Previously she was Independent Chairman of IXCellerate Ltd (Russian data centers) and gained much experience internationally as an exec in growing international technology businesses. Karen is also member of the 30% Club which supports boards to appoint more female directors and mentors women in tech through Rebus and Like-minded-Females. She mentors entrepreneurs through Kickstart Global and Neuro Nexus. You can find Karen on Linkedin: Karen Bach | LinkedIn

Bruce Gordon was appointed as the Independent Chairman of Pushpay on 20 February, 2014 and on 8 May, 2019 stood down from this position to assume the role of CEO and Executive Director, effective 1 June, 2019. Bruce has over 30 years’ experience in business holding senior positions with both SMEs and corporate organisations across Asia Pacific, the UK and the US. He has held various positions in other New Zealand technology companies, including Data Insight. A pioneer of many of the electronic banking services that consumers now enjoy, Bruce was Chairman of Paymark, Chief Manager Electronic Banking and Payments at Bank of New Zealand and has held senior roles at Eco-Products Group, Retail Financial Services (trading as Farmers Credit), National Australia Bank, ASB Bank and The Warehouse Group. He has extensive board experience, including with Vector Energy Solutions, The Warehouse Financial Services, The Merino Company of New Zealand and Bendon Group. Bruce is a Fellow of FINSIA and holds an MBA and a PGDipBus (Information Systems) both from the University of Auckland. Bruce lives with his family in Auckland.

Subscribe To Reef And Rivers iTunes  |  Stitcher  |  Google Podcast  |  Spotify  |  iHeart  |  Download This Episode Episode Description In Episode 2 of "Reef and Rivers" Greg Vinall chats with the Independent Chairman of the Wet Tropics Healthy Waterways Partnership, Professor Steve Turton about the 2018 results and what they're telling us. The 2018 Wet Tropics Report Card draws on data collected during the monitoring period from July 2016 to June 2017. This is the third consecutive data collection period that coincided with below average rainfall across the region and Greg and Steve talk about how this affects the Report Card scores for 2018 and how it bodes for the future of waterway health in the region. Podcast Timestamps 01:00   What the Wet Tropics Report Card is, and why it's important. 02:50   How the Report Card will be used 05:45   The results for 2018 06:35   Marine indicators and results 08:30   The connection between land-use and crown of thorns starfish 09:35   The reason marine inshore scores are low in 2018 11:55   Expectations for the 2019 Wet Tropics Report Card 12:55   Effect of the 2018 major rainfall event on waterway health 15:05   On-ground actions in the region and the impact on waterway health 17:05   How to get involved with the Wet Tropics Healthy Waterways Partnership 17:45   How to get a Report Card or get in touch with us

In today's Minutes: Tesla names independent chairman of board, Google to add jobs in NYC, and Monsters sues Coke. Plus, Bloomberg releases controversial best B-School list. --- Support this podcast: https://anchor.fm/watercoolesthq/support

George Mitchell helped end decades of lethal violence in Northern Ireland with the historic accord known as the Good Friday Agreement. In this episode Alan Alda talks with Sen. Mitchell about how he achieved that agreement through effective communication, and an understanding of human nature. He describes the essential elements of effective communication that brought together the governments of Ireland and the United Kingdom as well as the political parties of Northern Ireland, bringing an end to a seemingly endless cycle of violence. Sen. Mitchell served as a Special Advisor to President Clinton on Ireland, and acted as the Independent Chairman of the Northern Ireland Peace Talks. Support the show.

Karl, Brad and Kim chat with Ric Gloede the Independent Chairman of the WAFL’s Council of Presidents.